316 related articles for article (PubMed ID: 25367549)
1. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
[TBL] [Abstract][Full Text] [Related]
2. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
[TBL] [Abstract][Full Text] [Related]
4. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy.
Beltrand J; Beregszaszi M; Chevenne D; Sebag G; De Kerdanet M; Huet F; Polak M; Tubiana-Rufi N; Lacombe D; De Paoli AM; Levy-Marchal C
Pediatrics; 2007 Aug; 120(2):e291-6. PubMed ID: 17671040
[TBL] [Abstract][Full Text] [Related]
5. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
[TBL] [Abstract][Full Text] [Related]
6. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.
Oral EA; Gorden P; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Brown RJ
Endocrine; 2019 Jun; 64(3):500-511. PubMed ID: 30805888
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy.
Park JY; Javor ED; Cochran EK; DePaoli AM; Gorden P
Metabolism; 2007 Apr; 56(4):508-16. PubMed ID: 17379009
[TBL] [Abstract][Full Text] [Related]
12. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E
Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183
[TBL] [Abstract][Full Text] [Related]
13. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
14. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
Vatier C; Fetita S; Boudou P; Tchankou C; Deville L; Riveline J; Young J; Mathivon L; Travert F; Morin D; Cahen J; Lascols O; Andreelli F; Reznik Y; Mongeois E; Madelaine I; Vantyghem M; Gautier J; Vigouroux C
Diabetes Obes Metab; 2016 Jul; 18(7):693-7. PubMed ID: 26584826
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
[TBL] [Abstract][Full Text] [Related]
17. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
[TBL] [Abstract][Full Text] [Related]
19. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
Tchang BG; Shukla AP; Aronne LJ
Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
[TBL] [Abstract][Full Text] [Related]
20. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
